Results 111 to 120 of about 5,907 (256)

Risk of urinary tract infection with SGLT2 inhibitor initiation in patients with immune‐mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital‐based claims database

Journal of Diabetes Investigation, EarlyView.
In this target trial emulation of patients with immune‐mediated inflammatory diseases and type 2 diabetes, SGLT2 inhibitor initiation was not associated with a clear increase in UTI risk versus metformin, including across immunosuppressive therapy strata.
Hiroshi Tsushima, Nobuyuki Yajima, Takashi Nomiyama, Ryoko Sakai, Hisashi Noma, Akira Katagiri, Naoto Tamura   +6 more
wiley   +1 more source

Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐PATH study)

Journal of Diabetes Investigation, EarlyView.
Graphical abstract illustrating the study design, physiological rationale, and key findings of the D‐PATH trial. Dapagliflozin, an SGLT2 inhibitor, lowers HbA1c and body weight while increasing hematocrit and erythropoietin levels. Although an elevated hematocrit could theoretically increase blood viscosity and impair microcirculatory flow, ex vivo ...
Yuki Nakatani, Nobuyuki Banba, Shoya Ono, Tomoki Turumi, Megumi Hoshiai, Takushi Sugiyama, Takashi Tomoe, Hajime Tamiya, Naoyuki Otani, Hiroyuki Sugimura, Hidekazu Ikemiyagi, Yusuke Ohya, Koji Yokokawa, Shinichiro Ueda, Yoshimasa Aso, Yasuhiro Maejima, Takanori Yasu   +16 more
wiley   +1 more source

Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub‐analysis of Hokkaido‐TZP study data

Journal of Diabetes Investigation, EarlyView.
Tirzepatide achieved significant HbA1c reduction in Japanese patients with type 2 diabetes without obesity, regardless of baseline BMI. Weight reduction was BMI‐dependent and enhanced by dietary consultations. No patient developed underweight status during the 6‐month observation period.
Tomoe Abe, Fumika Maruyama, Eisuke Nishikawa, Miki Ito, Yukie Miyano, Hiroki Yamagata, Taiga Sasaki, Hidemitsu Sakagami, Akinobu Nakamura, Hiroshi Nomoto, on behalf of the Hokkaido‐TZP Study Group   +10 more
wiley   +1 more source

Real‐World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study

Diabetes, Obesity and Metabolism, EarlyView.
Juan Manuel Arteaga‐Diaz, Jose Luis Torres‐Grajales, Leobardo Sauque‐Reyna, Carlos Salamanca‐Carrillo, Luis Anguiano‐Medrano   +4 more
wiley   +1 more source

A case of maturity‐onset diabetes of the young with a pathogenic HNF1A variant and a coexisting NEUROD1 variant

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Maturity‐onset diabetes of the young (MODY) accounts for at least 1%–5% of diabetes cases and is usually caused by single gene variants. Accurate diagnosis of MODY is important for effective management, especially in young individuals who are lean and lack islet autoantibodies.
Tomofumi Takayoshi, Yushi Hirota, Kenji Sugawara, Aki Sugano, Mika Ohta, Takehito Takeuchi, Akane Yamamoto, Wataru Satake, Yutaka Takaoka, Wataru Ogawa   +9 more
wiley   +1 more source

Monocyte dipeptidyl peptidase 4 activity is associated with urinary albumin excretion in type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
This study examined whether dipeptidyl peptidase 4 (DPP4) characteristics in peripheral blood monocytes relate to renal parameters. Monocyte DPP4 activity was independently associated with urinary albumin excretion in patients with type 2 diabetes, suggesting that monocytes may function as a cellular link between DPP4 and diabetic kidney disease ...
Hideyuki Okuma, Takahiro Tsutsumi, Kyoichiro Tsuchiya   +2 more
wiley   +1 more source

The stimulatory action of tolbutamide on Ca2+-dependent exocytosis in pancreatic beta cells is mediated by a 65-kDa mdr-like P-glycoprotein [Elektronisk resurs]

, 1999
Intracellular application of the sulfonylurea tolbutamide during whole-cell patch-clamp recordings stimulated exocytosis >5-fold when applied at a cytoplasmic Ca2+ concentration of 0.17 microM. This effect was not detectable in the complete absence of
Bertorello, Alejandro,, Holmes, William E,, Braun, Matthias,, Renström, Erik,, Rorsman, Patrik,, Barg, Sebastian,, Bokvist, Krister,, Eliasson, Lena,, Berggren, Per-Olof,, Köhler, Martin,, Thévenod, Frank,   +10 more
core   +1 more source

Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ‐protective effects, leading to increased use in high‐risk populations.
Takuma Koinuma, Manato Yoshida, Manabu Akazawa   +2 more
wiley   +1 more source

The Generics Revolution and the New Economic Geography of the Global Pesticide Industry

Journal of Agrarian Change, EarlyView.
ABSTRACT The global pesticide industry transformed from one dominated by patented products and legacy multinationals with strong manufacturing bases in the United States and EU to one dominated by generic products produced in India and China. We use proprietary market research data, data from regulatory filings, industry press and bilateral trade data ...
Christian Berndt, Marion Werner, Finn Mempel, Annie Shattuck, Zackary Okun Dunivin   +4 more
wiley   +1 more source

The Sulfonylurea Drug, Glimepiride, Stimulates Glucose Transport, Glucose Transporter Translocation, and Dephosphorylation In Insulin-Resistant Rat Adipocytes In Vitro [PDF]

, 1993
Wied, Susanne, Müller, Günter
core